Skip to main content

Purple Innovation Inc

For the period ended Mar 31, 2024. Filed May 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 7, 2024

PRPL$1.80-0.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity

(unaudited – in thousands)

Class A · Class B · Additional · Total
Common Stock · Common Stock · Paid-in · Accumulated · Stockholders’ · Noncontrolling · Total
SharesPar ValueSharesPar ValueCapitalDeficitEquityInterestEquity
Balance – December 31, 2023105,507$11205$—$591,380$(475,969)$115,422$185$115,607
Net loss—————(50,217)(50,217)(51)(50,268)
Stock-based compensation————492—492—492
Issuance of stock for Intellibed acquisition1,500————————
Issuance of stock under equity compensation plans473———(115)—(115)—(115)
Impact of transactions affecting NCI————(33)—(33)33—
Balance – March 31, 2024107,480$11205$—$591,724$(526,186)$65,549$167$65,716
Class A · Class B · Additional · Total
Common Stock · Common Stock · Paid-in · Accumulated · Stockholders’ · Noncontrolling · Total
SharesPar ValueSharesPar ValueCapitalDeficitEquityInterestEquity
Balance – December 31, 202291,380$9448$—$529,466$(355,212)$174,263$908$175,171
Net loss—————(25,933)(25,933)(119)(26,052)
Stock-based compensation————1,192—1,192—1,192
Issuance of stock under equity compensation plans265————————
Issuance of stock upon underwritten offering, net of costs13,4002——57,198—57,200—57,200
Impact of transactions affecting NCI————(103)—(103)103—
Balance – March 31, 2023105,045$11448$—$587,753$(381,145)$206,619$892$207,511
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.